ABSTRACT
Purpose: Various parameters have been proposed to predict the outcome of patients with coronavirus disease. The aim of this study was to evaluate the utility of the age-adjusted CCI score and biochemical parameters for predicting outcomes for COVID-19 patients on admission. Patients and methods: A total of 511 patients were included in the study. Only swab or serological tests positive patients were included. The clinical characteristics of the patients were compared between survival and non-survival COVID-19 inpatients. Hemoglobin, platelet, sedimentation, creatinine, AST, ALT, LDH, CK, albumin, ferritin, lymphocyte, neutrophil, CRP (1-5;5-10;10-20 × upper limit), procalcitonin (5-10;10-20; > 20 × upper limit), D Dimer (> 2 × upper limit), age, gender, chronic diseases and CCI scores were compared between the two groups. Results: 68 patients died and 443 patients survived. Mean age was 74.3±7.3 years in survival group and 76.7±8.0 in nonsurvival group. Age, male sex, ischemic heart disease (CHD), chronic kidney disease and active malignancy was statistically higher in non-survivor group. The biochemical parameters was compared in survival and nonsurvival group. CCI score, AST, LDH, CK, Ferritin, CRP are significantly higher and albumin, lymphocyte levels are significantly lower in nonsurvival group. D-dimer and procalcitonin levels are significantly higher in nonsurvival group. CCI score and neutrophil, creatinine, ALT, AST, d-dimer and procalcitonin elevations were correlated. Low albumin and lymphocyte levels were correlated with the CCI score. There was no significant correlation between ferritin, sedimentation, CRP levels and CCI score. A multivariate logistic regression analysis indicated that anaemia, elevated CRP (> 10-20 × upper limit), procalcitonin (> 5-10 × upper limit), ALT, AST levels and higher CCI score were independent risk factors for mortality in COVID-19 patients. Conclusion: Anaemia, elevated CRP, procalcitonin levels, ALT, AST levels and higher CCI score were found independent risk factors for mortality in COVID-19 patients.
ABSTRACT
Aim: The severe acute respiratory syndrome novel corona virus-2 (SARS-nCoV-2) which is an enveloped RNA virus was defined as the cause of Corona Virus Disease-2019 (COVID-19). Gastrointestinal (GI) symptoms can also be observed in COVID-19 patients. This study was performed to evaluate the association between GI symptoms and laboratory results. Methods: This retrospective study was carried out in the University of Health Sciences Turkey, Istanbul Haseki Health Training and Research Hospital between 11th March and 1st June 2020. This study consisted of a total of 159 patients with COVID-19. COVID-19 infection was defined via a positive nasal and pharyngeal swab test. All symptoms of patients were recorded. Study patients were divided into 2 groups according to the presence of GI symptoms or not. Results: There were 41 patients in the group with GI and 118 were in the group without GI symptoms. Nausea and/or vomiting were observed in 29, diarrhea in 20 and abdominal pain in 10 patients. Percentages of anosmia (loss of smell sense) and ageusia (loss of taste sense) increased in patients with GI symptoms than the other group (p=0.005 and <0.0001). The mean serum aspartate amino transferase (AST) level elevated in COVID-19 patients with GI symptoms (p=0.022). Conclusion: Anosmia and ageusia increased significantly in COVID-19 patients with GI. Serum C-reactive protein and AST levels statistically increased in COVID-19 patients with GI.